Literature DB >> 18507078

Role of percutaneous transhepatic biliary drainage in patients with obstructive jaundice caused by local recurrence of gastric cancer.

Tomoki Makino1, Kazumasa Fujitani, Toshimasa Tsujinaka, Motohiro Hirao, Masaki Kashiwazaki, Shoji Nakamori, Masakazu Ikenaga, Hideyuki Mishima, Norikazu Masuda, Toshiro Sawamura.   

Abstract

BACKGROUND/AIMS: We reviewed the medical records of patients with obstructive jaundice caused by the local recurrence of gastric cancer to clarify the role of percutaneous transhepatic biliary drainage (PTBD).
METHODOLOGY: Eleven patients with a mean age of 60.1 years (range: 51-71 years) underwent PTBD because of obstructive jaundice caused by the extrahepatic recurrence of gastric cancer.
RESULTS: Jaundice was relieved in all the patients, and the serum total bilirubin (T-bil) level decreased from 12.2 to 2.1 mg/dL. No major complications associated with the execution of PTBD occurred. Although various symptoms caused by jaundice, such as anorexia, itching, nausea, abdominal pain, and fever, were relieved in all the patients within one week after PTBD, general fatigue persisted in 3 patients and abdominal fullness persisted in one. Seven of the 11 patients were discharged from the hospital after the execution of PTBD and remained at home for a median of 93 days. The median survival time (MST) of the remaining 4 patients who could not be discharged was 48 days. Chemotherapy was added in 5 patients after the execution of PTBD; these patients exhibited a significantly longer MST of 247 days, compared to 62 days among the patients who did not receive chemotherapy (P=0.0176).
CONCLUSIONS: PTBD was safely conducted and improved the quality-of-life of patients with obstructive jaundice caused by the local recurrence of gastric cancer. Furthermore, the use of chemotherapy after PTBD might prolong patient survival although RCT (randomized controlled trial) study should be performed to assess the precise effect of chemotherapy after PTBD.

Entities:  

Mesh:

Year:  2008        PMID: 18507078

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Clinical outcome of malignant biliary obstruction caused by metastatic gastric cancer.

Authors:  Kazuhiro Migita; Akihiko Watanabe; Tetsuya Yoshioka; Shoichi Kinoshita; Takao Ohyama
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

2.  Biliary intraductal metastasis from advanced gastric cancer: radiologic and histologic characteristics, and clinical outcomes of percutaneous metallic stent placement.

Authors:  JooYeon Lee; Dong Il Gwon; Gi-Young Ko; Jong Woo Kim; Kyu-Bo Sung
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

Review 3.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

4.  The Clinical Benefit of Percutaneous Transhepatic Biliary Drainage for Malignant Biliary Tract Obstruction.

Authors:  Ivan Nikolić; Jelena Radić; Andrej Petreš; Aleksandar Djurić; Mladjan Protić; Jelena Litavski; Maja Popović; Ivana Kolarov-Bjelobrk; Saša Dragin; Lazar Popović
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

5.  Percutaneous placement of self-expandable metallic stents in patients with obstructive jaundice secondary to metastatic gastric cancer after gastrectomy.

Authors:  Hyun Pyo Hong; Tae-Seok Seo; In-Ho Cha; Jung Rim Yu; Young Jae Mok; Joo Hyeong Oh; Se Hwan Kwon; Sam Soo Kim; Seung Kwon Kim
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

6.  Clinical outcomes and prediction of survival following percutaneous biliary drainage for malignant obstructive jaundice.

Authors:  Guang Yuan Zhang; Wen Tao Li; Wei Jun Peng; Guo Dong Li; Xin Hong He; Li Chao Xu
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.